Minds and Mentors Program for Opioid Use Disorder

(MiMP Trial)

Recruiting at 2 trial locations

Overseen By Mercy N Mumba, PhD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Recruiting

Sponsor: University of Alabama, Tuscaloosa

No Placebo Group

Trial Summary

What is the purpose of this trial?

This trial tests the Minds and Mentors Program, a group therapy that uses mindfulness and peer support, in people with opioid use disorder who are on medication. The goal is to see if it helps them stick to their medication, reduces relapse rates, and lowers stress and cravings. Mindfulness-based relapse prevention (MBRP) includes the teaching and practice of mindfulness meditation to help patients change their relationship to drug cravings and other negative emotional states.

Eligibility Criteria

This trial is for adults over 19 with opioid use disorder who are currently on medication-assisted treatment (like methadone or buprenorphine). They must be stable on their medication, able to attend 12 therapy sessions and follow-ups for 9 months, have internet access, and not be in immediate need of intensive care like detox. Pregnant women, those with unstable medical conditions or active psychosis, suicidal thoughts, or significant cognitive impairment cannot join.

Inclusion Criteria

Are within maintenance phase of MOUD (not actively detoxing)

I am 19 years old or older.

Opioid Use disorder diagnosis based on DSM-V criteria in the past 30 days

Exclusion Criteria

Actively suicidal or homicidal

Active psychosis

I am not currently pregnant.

Treatment Details

Interventions

• Minds and Mentors (Behavioral Intervention)
• Twelve Step Intervention Group (Behavioral Intervention)

Trial Overview The study tests the Minds and Mentors Program against a Twelve Step Facilitation program for people using medications to treat opioid addiction. Participants will randomly receive one of these treatments in groups of five. The goal is to see if the program helps stick to treatment better, reduces relapse and cravings, lowers anxiety/stress/depression levels, and affects cortisol related to drug cues.

Participant Groups

Group I: Mindfulness based relapse prevention and peer mentoring Experimental Treatment 1 Intervention

Treatment will utilize a group format. The twelve-week mindfulness based relapsed prevention group therapy intervention is co-led by a licensed counselor and a peer mentor for eight weeks, followed by group sessions led by peer mentors for an additional four weeks.

Group II: 12 Step Treatment Program Active Control 1 Intervention

Participants in the attentional control group will attend 12 weeks of a enhanced 12 step treatment program.

Who Is Running the Clinical Trial?

University of Alabama, Tuscaloosa

Lead Sponsor

Trials

49

Recruited

17,900+

University of Alabama at Birmingham

Collaborator

Trials

1,677

Recruited

2,458,000+

Tuscaloosa Veterans Affairs Medical Center

Collaborator

Trials

6

Recruited

690+

Pathway Healthcare, LLC

Collaborator

Trials

1

Recruited

240+